Dx Deal Review 2024

2024: The Year of AI-Driven Early Detection, Multi-Omic Data Integration, and Precision Diagnostics.


Dx Deal Review 2024

Download Request

US Biopharma VC landscape

The US biopharma VC landscape has been transformed over the last four years. The free-flowing capital of the pandemic sugar rush era peaked in Q4 2020, after which the IPO window snapped firmly shut in the last quarters of 2022. The next year for biotech was even worse in most respects: IPOs down, VC down, M&A down, licensing deals down. However, despite lower deal numbers and total capital deployment, reported valuations appeared to hold firm and start recovering in late 2023. This white paper provides insightful and in-depth analysis of the US biopharma VC landscape.


US Biopharma VC landscape

Download Request

Dx Deal Review Q4 2024

Early detection, At-Home Testing and Smart Phone/ Wearable technology
Expanding non-invasive diagnostics in healthcare


Dx Deal Review Q4 2024

Download Request

Trends and Outlook of Licensing and M&A in the South Korean Pharmaceutical and Biotech Sector

Over the past five years, the South Korean pharmaceutical and biotech sector has emerged as a hotbed for Licensing and Mergers and Acquisitions (M&A) activity, attracting interest from both domestic and international players. Its unprecedented growth is fuelled by a combination of innovation, government support, and market expansion strategies, alongside the strategic need to access advanced technologies and global markets. This white paper provides an in-depth analysis of the key trends, drivers, and notable transactions that have shaped this dynamic sector, and highlights how international companies can benefit from this thriving market.

 

 

 


Trends and Outlook of Licensing and M&A in the South Korean Pharmaceutical and Biotech Sector

Download Request

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dx Deal Review Q3 2024

Leveraging Non-Invasive Testing in CNS and Endometriosis – Ongoing Research, Data Sharing
and AI Drive Diagnostic Innovations


Dx Deal Review Q3 2024

Download Request

Private Equity’s Path in European Specialty Pharma M&A: Mastering 2024’s Challenges and Seizing New Opportunities

The European specialty pharma M&A landscape is undergoing significant transformations, with private equity firms facing new and unprecedented challenges. This white paper examines the current state of private equity within the sector, identifying the key obstacles and trends reshaping investment strategies.

 


Private Equity’s Path in European Specialty Pharma M&A

Download Request